Amplia Therapeutics Ltd.ASX: ATX

Granting of Key Patent in Europe and Japan

· Issued by Amplia Therapeutics Ltd.

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Amplia Therapeutics Ltd. has announced the granting of a key patent in Europe and Japan for its FAK inhibitor narmafotinib, which describes a specific chemical form of the drug. The patent was granted by the Japanese Patent Office and is expected to be granted in Europe shortly thereafter.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Amplia Therapeutics Ltd. on 6ix

Earlier from Amplia Therapeutics

Later from Amplia Therapeutics

All Amplia Therapeutics news releases